focal dystonia
Conditions
Interventions
Cognitive behavioral therapy
Sponsors
National Center Hospital, National Center of Neurology and Psychiatry
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Subjects diagnosed with focal dystonia by a neurologist 2) Subjects aged 18 to 65 years at the time of obtaining consent 3) Subjects currently visiting our hospital 4) Subjects whose attending physician has determined that they need to reduce anxiety and depression, and whose Hospital Anxiety and Depression Scale score is 8 or higher 5) Subjects whose medication dosage has not changed for more than three months at the neurology dystonia clinic 6) Subjects who understand the explanation regarding participation in the study and are able to consent
Exclusion criteria
Exclusion criteria: 1) Psychotic disorder present at the time of screening (as diagnosed by a doctor) 2) Cognitive impairment MoCA-J score of 20 or less 3) Persons diagnosed with intellectual disability by their doctor 4) Manic episode present at the time of screening (as diagnosed by a doctor) 5) Severe substance use disorder present at the time of screening (as diagnosed by a doctor) 6) Severe suicidal ideation (as diagnosed by a doctor) 7) Persons with other problems that would prevent cognitive behavioral therapy from being implemented
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse events: Adverse events refer to any untoward occurrence during treatment, regardless of whether it is causally related to the treatment. Data are collected by self-report from patients. Dropout: This refers to a participant withdrawing from treatment or the study midway. The reasons for dropout are investigated by telephone interview. Hospital Anxiety and Depression Scale: This is a self-report questionnaire to assess the level of anxiety and depression. This scale allows for scores from 0 to 21 for each subscale (anxiety and depression), for a total of 42 points. For each subscale (anxiety and depression), higher scores indicate a higher severity of the symptom. (0-7 points: normal range (no or mild symptoms), 8-10 points: moderate symptoms, 11 points or more: severe symptoms) | — |
Countries
Japan
Contacts
Public ContactYohei Mukai
National Center of Neurology and Psychiatry Hospital Department of Neurology
Outcome results
None listed